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Cardiovascular diseases are one of the leading causes of morbidity and mortality in women after menopause and 56% of all causes
of death in Western European countries. Nowadays, with increasing life span, women spend approximately one-third of their life-
time in postmenopausal state; therefore, the development of new strategies to improve the prevention and treatment ofmenopause-
associated pathologies is important topic in clinical practice. The studies to assess the safety of hormone replacement therapy in
women with estrogen deficiency have not been conclusive due to the relative contraindications; therefore, hormone replacement
therapy is prescribed only in selected cases and for a limited time. For this reason, today women are encouraged to use naturally
available compounds to prevent or to attenuate menopausal symptoms and correlated pathologies, with fewer side effects. Among
these compounds, berberine, an isoquinoline alkaloid derived from plants of the generis Berberis, has been recognized as being
capable of decreasing oxidative stress, LDL, triglycerides, and insulin resistance and of improving the mood. This review describes
the cellular and clinical effects associated with the use of berberine, which suggest that this molecule could be an effective natural
supplement to ensure a smooth peri- and postmenopausal transition.
1. Introduction
Cardiovascular diseases are one of the leading causes of
morbidity and mortality in women after menopause and
56% of all causes of death in Western European countries
[1]. Menopause is characterized by an altered hormonal
status and a subsequent decrease in life quality affecting each
woman differently. Specifically, the decline and eventual ces-
sation of estrogen production are associated with the appear-
ance of uncomfortable symptoms (hot flashes, night sweats,
breast tenderness, vaginal dryness, irregular menses, mood
changes, and vaginal atrophy) as well as pathologies such as
osteoporosis, heart disease, hypercholesterolemia, endothe-
lial dysfunction, vascular inflammation, hyperglycemia, and
depression [2]. Currently, women may expect to spend more
than a third of their lives after menopause; therefore, the
understanding of menopause-associated pathologies and the
development of new strategies to improve the treatment of
menopause-associated symptoms are important topics in the
clinical practice. Results from different studies indicate that
the use of hormone replacement therapy (HRT) in men-
opause needs to be carefully assessed and risks and benefits
of the therapy should be evaluated by the clinician for each
individual woman. Clearly, the possible problems associated
withHRT in a subpopulation in womenmay be attenuated by
other molecules, safer than estrogens, as well as by lifestyle
modifications, such as diet, food supplements, and exercise
[3]. In recent years, there has been renewed interest in
the potential of purified natural products to provide health
and medical benefits and to prevent disease. Antioxidant
compounds have been shown to be of great benefit in women
experiencing menopausal symptoms [4].
Berberine (BBR), a quaternary ammonium salt from the
protoberberine group of isoquinoline alkaloids (5,6-dihy-
drodibenzoquinolizinium derivative) found in the bark, rhi-
zomes, roots, and stems of Berberis vulgaris L. (Berberi-
daceae), exhibits many different types of biological activities
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[5]. Among them, the best characterized ones are antioxidant,
anti-inflammatory, cholesterol-lowering, antihyperglycemic,
and antidepressive effects.
This paper will discuss the studies that have shown the
potential benefits of berberine supplementation for the
reduction, at least partially, of menopause-associated pathol-
ogies (oxidative stress, inflammation and hypercholesterole-
mia-related cardiovascular diseases, hyperglycemia-related
diabetesmellitus type 2, and depression) and for the improve-
ment of quality of life in menopausal women.
2. Role of Berberine in Oxidative Stress
Estrogen deficiency increases cardiovascular risk, as a result
of atherogenic modifications of plasma lipid profile, activa-
tion of the renin-angiotensin system, and overproduction
of reactive oxygen species (ROS) which quench nitric oxide
(NO) [6, 7]. Overproduction of ROS has been shown in
pathological situations and can be highly injurious to adja-
cent structures in cells, including lipid membranes, DNA,
and proteins [8]. Increased oxidative stress and reduced
NO bioavailability are important contributing factors of
menopause-related endothelial dysfunction, atherosclerosis,
hypertension, cardiovascular, and renal diseases [9, 10].
Impaired vascular function due to ROS overproduction
which occurs during estrogen deficiency could be normalized
by HRT in women and animal models of menopause [11,
12]. In fact, following the onset of either permanent or
transient estrogens deprivation, oxidative stress increases sig-
nificantly [4]. Serum concentrations of inflammatory cytok-
ines and prooxidant biomarkers such as glutathione, 4-hy-
droxynonenal, andmalondialdehyde were found to be higher
in postmenopausal than in premenopausal women [13].
The elevation of cytokines and prooxidant makers suggests
that there is a high degree of oxidative stress in the post-
menopausal state [13, 14].
One of the major sources of ROS production in cells is a
family of membrane-associated enzymatic complexes called
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (NOX) [15]; its activation is often associated with
high levels of fatty acids, cholesterol, glucose, or advanced
glycation end products (AGEs), all linked tomenopausal state
[16–18]. Among various NOX isoforms, BBR was reported to
suppress the overexpression of NOX 2, 4 and to decrease ROS
production inmacrophages and endothelial cells upon stimu-
lation with inflammatory stimuli [19, 20]. In endothelial cells,
BBR attenuates LDL oxidation induced by ROS and reduces
the collapse of mitochondrial membrane potential, the chro-
mosome condensation, the cytochrome C release, and the
caspase-3 activation [21]. Circulating endothelial micro-
particles (EMPs), vesicular structures found in plasma from
patients with vascular diseases so utilized as a surrogate
marker of endothelial dysfunction, are oxidative stress induc-
ers; they promote upregulation of NOX4 expression and ROS
production. It has been reported that BBR reversed NOX4-
derived ROS production in human umbilical vein endothelial
cells (HUVECs) [22].
NOX could be negatively regulated by adenosine mon-
ophosphate-activated protein kinase (AMPK) activation
[23, 24]; in fact AMPK activators, such as metformin, may
exert their cardiovascular protective function through NOX
inhibition [25]. AMPK pathway is activated by BBR [26] and
it seems to play a pivotal role in mediating its antioxidant
activity [27, 28].
AMPKplays also an important role in regulating function
of NO synthesis in endothelial cells. In fact, AMPK is an
upstream kinase of endothelial nitric oxide synthase (eNOS)
which promotes the phosphorylation of eNOS at Ser1177 site
aswell as the formation of eNOS andHSP90 complex andNO
production [9, 29]. Menopause-related decrease in estrogen
receptors correlates with lower eNOS expression and activa-
tion [30] in both animal and humanmodels ofmenopause [7,
12] as eNOS activity is notably regulated by estrogens through
the modulation of the eNOS/caveolin-1 (Cav-1) complex for-
mation [31]. Zhang and colleagues observed that in HUVECs
BBR ameliorates palmitate-induced endothelial dysfunction
by upregulating eNOS and downregulating NOX4 through
the activation of AMPK [32]. In both cultured endothelial
cells and blood vessels isolated from rat aorta BBR enhanced
eNOS phosphorylation and attenuated high glucose-induced
generation of ROS, cellular apoptosis, NF-𝜅B activation, and
expression of adhesion molecules through AMPK signaling
cascade activation, a key event in preventing oxidative and
inflammatory signaling [33].
Besides NADPH oxidase downregulation and NO pro-
duction, AMPK activation has been linked to upregulation of
the antioxidant enzyme superoxide dismutase (SOD) [34, 35],
which induces the dismutation of anion superoxide in hydro-
gen peroxide. An increased SOD expression in BBR treated
diabetic mice was observed [36, 37]. Glutathione (GSH) is
another antioxidant enzyme which helps to maintain the
balance of redox state in organisms and it is a substrate
of glutathione peroxidase (GSH-Px) in the clearance of
peroxides [38]. BBR treatment promotes a GSH-Px and SOD
hyperactivation in the liver of mice [39], attenuates H
2
O
2
-
induced ROS production, and increases detoxifying enzymes
GSH-Px and SOD in NSC34 motor neuron-like cells [40].
3. Role of Berberine in
Cardiovascular Disease Risk
The increased cardiovascular disease risk at the menopause
is associated with decreased ovarian function [41, 42] and is
in part due to arterial dysfunction and a less favorable blood
lipid profile. Exogenous estrogen and progesterone, in the
form of HRT, have been shown to reduce plasma concen-
trations of LDL cholesterol and increase concentrations of
HDL cholesterol [43] even if their use in menopause is still
object of debate because of the increased risk of breast cancer,
ictus, ischaemic cardiomyopathy, and thrombus detachment
[44, 45].
High levels of low-density lipoprotein (LDL) and their
oxidized counterpart, oxidized LDL (oxLDL), in the blood
vessels represent a major risk factor for endothelial dys-
function and atherosclerosis [46]. Inactivity of LDL receptor
(LDLR) or its low-level expression initiates accumulation of
LDL in blood vessels [47]. On the other hand, the receptor of
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oxLDL, lectin-like oxidized low-density lipoprotein receptor-
1 (LOX-1) identified as the main endothelial receptor for
oxLDL and also present in macrophages and smooth muscle
cells (SMC), activates a proatherogenic cascade by inducing
endothelial dysfunction, SMC proliferation, apoptosis, and
the transformation of macrophages into foam cells and
platelet activation via NF-𝜅B activation [48]. LOX-1 contains
a lectin-like extracellular C-terminal domain which interacts
with oxLDL, proteolytically cleaved and released as a soluble
circulating form (sLOX-1) that reflects the increased expres-
sion of membrane-bound receptors and disease activities
[49].
Proinflammatory and oxidative stimuli related to athero-
genesis [48] such as TNF𝛼 or interferon 𝛾 promote the
oxLDL formation which in turn develops a vicious cycle by
the activation of LOX-1 linked to NF-𝜅B to promote tran-
scription of proinflammatorymolecules [50]. In arterial walls
oxidative stress and inflammation are closely linked; LOX-1
is undetectable in healthy vessels but overexpressed in ath-
erosclerotic lesions and in acute coronary syndromes [51].
Thus circulating sLOX-1 could be a potential cardiovascular
disease biomarker [49].
It has been reported that in cultured placental cells a
combination of ethinyl estradiol and desogestrel increases the
expression and functional activity of LDLR and decreased the
expression of LOX-1 [52–54].
BBR elevates LDLR expression in human liver cells [55]
through ERK activation with a sterol regulatory element
binding proteins (SRPB) independent mechanism [56, 57].
In another report it has been reported that BBR induces
proprotein convertase subtilisin/kexin type 9 (PCSK9), an
enzyme that posttranscriptionally upregulates LDLR and
SREBP-2 [58]. In accordance with previous cited studies, it
has been showed that in rat livers a combination of BBR with
simvastatin increased the LDLR gene expression to a level
significantly higher than that in monotherapies [59].
In human macrophage-derived foam cells treated with
oxLDL, BBR inhibits the expression of LOX-1 [60, 61] as well
as the oxLDL uptake of macrophages and reduces foam cell
formation in a dose-dependent manner [61] by activating the
AMPK-SIRT1-PPAR𝛾 pathway [62]. Chi and colleagues [63]
demonstrated that BBR combined with atorvastatin is more
effective in diminishing LOX-1 expression than atorvastatin
alone in monocyte-derived macrophages both in vitro and
in vivo in rats through modulation of endothelin-1 receptor
[62]. It is still unknown whether BBR could affect LOX-1
expression in endothelial cells.
BBR improves also the survival of TNF𝛼-treated endothe-
lial progenitor cells (EPCs) via the activation of PI3K/AKT/
eNOS signaling pathway [64] possibly throughAMPKactiva-
tion.Wu and colleagues showed, both in vitro and in vivo, that
BBR reduces the leukocyte-endothelium adhesion and vascu-
lar cell adhesion molecule-1 (VCAM-1) expression induced
by lipopolysaccharide (LPS). BBR was further confirmed to
inhibit the nuclear translocation and DNA binding activity
of LPS-activated NF-𝜅B signaling pathway [65].
The lipid-lowering activity of BBR, alone or in associa-
tion with other nutraceuticals, has been clearly confirmed
in a relatively large number of randomized clinical trials,
involving a large part of women (usually a half, almost all
in peri- or postmenopausal age) [66]. In a large placebo-
controlled, randomized clinical trial, it has been reported
that short-term consumption of a combined nutraceutical
containing isoflavones and BBR out on 120mild dyslipidemic
postmenopausal women significantly lowered plasma total
cholesterol (13.5% ± 0.7 versus 0.2% ± 0.5), LDL cholesterol
(12.4% ± 1.5 versus 0.8% ± 0.7), and TG (18.9% ± 2.5 versus
1.3% ± 1.2) improving menopausal symptoms compared with
placebo [67].
In a subsample of the same study, it is shown that the
assumption of isoflavones and BBR also improved the serum
levels of matrix metalloproteinases, known to promote the
invasion of inflammatory cells by degrading the extracellular
matrix [2].
The anti-inflammatory effect of BBR was also confirmed
in patients with acute coronary syndrome following percuta-
neous coronary intervention [68].
Thus, BBR seems to be a promising preventive treatment
in the initial key steps of atherogenesis.
4. Role of Berberine in
Diabetes Mellitus Type 2
Different studies have shown that the incidence of dia-
betes mellitus type 2 (T2DM) is higher among menopausal
women [69, 70]. In fact, estrogen influences not only vas-
cular functions but also insulin sensitivity [71]. T2DM is a
chronic disease characterized by hyperglycemia and insulin
resistance in peripheral tissues, particularly in the liver,
muscles, adipocytes, and pancreatic 𝛽-cells. Individuals with
insulin resistance have either decreased levels or absence of
insulin receptor expression (InsR) [72–74] and subsequent
hyperglycemia. Oxidative stress participates in development
and progression of T2DM, in which changes of SOD and
catalase (CAT) were noted in T2DMmice [36].
It has been reported that taking a low dose of combined
HRT (a combination of estrogens and progesterone) led
to a decreased risk of developing diabetes and to better
glucose control in postmenopausal women [75]. Mora´n and
colleagues compared the effects of estradiol and genistein
treatments on insulin signaling pathway in the cerebral
cortex of ovariectomized young and aged female rats. They
observed that aging decreases the translocation of the insulin
dependent glucose transporter-4 (GLUT4) and 17𝛽-estradiol
but not genistein which favours GLUT4 translocation [76].
BBR exhibited a high hypoglycemic potential; it has been
shown that BBR activates AMPK with subsequent induction
of glycolysis [77]. AMPK, as an intracellular energy receptor,
has attracted more attention and become a new target for the
treatment of diabetes and its cardiovascular complications
due to its regulatory effect on endothelial cell function and
energy homeostasis. In H9c2 myoblast cell line treated with
insulin to induce insulin resistance, BBR attenuated the
reduction in glucose consumption and glucose uptake at least
in part via stimulation of AMPK activity [78]. BBR enhanced
acute insulin-mediated GLUT4 translocation and glucose
transport in insulin-resistant myotubes through activation of
AMPK and PI3K pathway [79].
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Besides the role in AMPK signaling, Kong and colleagues
showed that BBR increased insulin receptor (InsR)messenger
RNA and protein expression in a variety of human cell lines
and hepatitis B virus transfected human liver cells [80]. In
a clinical study, the same group observed that BBR signifi-
cantly lowered fasting blood glucose (FBG), hemoglobin A1c,
triglycerides, and insulin levels in patients with T2DM as well
as metformin and rosiglitazone (a combination commonly
used for the T2DM therapy); the percentages of peripheral
blood lymphocytes expressing InsR were significantly ele-
vated after therapy [81].
BBR exhibited similar hypoglycemic potential as gliben-
clamide (an anti-T2DM drug that stimulates the release of
insulin) to lower area under the curve of the fasting blood
glucose in the kidney, liver, and brain of mice with T2DM
[36].
The dose-dependent antidiabetic properties of BBR have
been clearly confirmed in a relatively large number of ran-
domized clinical trials, involving a large number of women
(usually 50%, almost all in peri- or postmenopausal age) [82].
Thus, on the basis of the available evidence, we can rea-
sonably conclude that BBR could be an ideal supplementation
for T2DM since it acts with a mechanism different from the
three drugs commonly utilized in therapy: glibenclamide,
metformin, and rosiglitazone.
5. Role of Berberine in Depressive Disorder
During the menopausal transition between 15% and 50%
of women experience depressive symptoms; in 15% to 30%
of perimenopausal women, they are severe enough to be
regarded as a depressive disorder. Fluctuations in gonadal
hormone levels are thought to contribute to these depressive
conditions and HRT is commonly used to alleviate climac-
teric symptoms [83].
A combination of interactions betweenneurotransmitters
[84], neuropeptides [85], oxidative and nitrosative stress [86],
and cytokines [87] are thought to take part in pathogenesis of
depression. It is theorized that the additive effect of enhancing
neurotransmission in three monoamine systems (serotonin,
norepinephrine, and dopamine) may lead to improved effi-
cacy and quicker onset of antidepressant response [88].
Clinical studies have reported that patients with depression
presented also oxidative disturbances such as elevated lipid
peroxidation products and reduced levels of SOD [89, 90].
NF-𝜅B activity is regulated at least in part by the intensity
of intracellular oxidative and nitrosative stress and, in turn,
controls the regulation of genes encoding proteins involved
in immune and inflammatory responses [91]. Depressed
patients often display enhanced cytokine levels including
interleukin-6 (IL-6), C-reactive protein, interleukin-1-beta
(IL-1𝛽), and TNF𝛼; they can enter the brain and may cause
alterations of the metabolism of serotonin and dopamine
[92]. Thus these studies showed a correlation between oxida-
tive and nitrosative stress, increased levels of cytokines, and
altered levels of biogenic amines.
Mechanistically, estrogen plays an important role in
mood and cognitive regulation [93]. It is reported that
monoamine oxidase-A (MAO-A) total distribution volume,
an index of MAO-A density, is elevated in perimenopausal
women [94].
BBR inhibited the immobility period in mice in both
forced swim and tail-suspension test, two animal models of
depression, in a dose independent manner [95, 96]. Among
the reported bioactivities of BBR there is the inhibition of
MAO-A enzyme activity [97]. In fact acute and chronic
administration of BBR in mice resulted in increased levels of
norepinephrine, serotonin, and dopamine, neurotransmitters
induced by MAO-A enzyme [95]. In accordance with Kulka-
rni and colleague data, Arora and Chopra showed the protec-
tive antidepressant-like effect of BBR against the reserpine-
induced biogenic amine depletion (a monoamine depletor
commonly used to induce depression in animals [98]) and
against oxidative nitrosative stress-mediated inflammatory
cascade and apoptotic signaling pathway in rats [99].
Recently, the important role of endoplasmic reticulum
protein sigma-1 receptors (sigma receptors) in the modu-
lation of various neurotransmitters has been identified. It
seems to be a promising target for the pathophysiology of
neuropsychiatric disorders, in particular for depression, and
sigma-1 receptor modulators are considered the drugs of the
future for the treatment of major depression and anxiety. It is
reported that BBR has an effect on sigma receptor-1 similar to
many synthetic antidepressant drugs [100].
However, at the best of our knowledge, there are no avail-
able data on the evaluation of the potential antidepressant
effects of BBR in human.
6. Berberine Tolerability and Safety
Representative figures to summarize the molecular pathways
modulated by BBR and its effects on organs and tissues
are shown (Figures 1 and 2). Standard doses of BBR are
usually well-tolerated and adverse reactions are rare. On
the contrary, high doses have been associated with arterial
hypotension, dyspnoea, flu-like symptoms, gastrointestinal
discomfort, constipation, and cardiac damage. The LD50
(lethal dose 50) of highly purified formulation of berberine
sulfate is 25mg/kg in mice while the one of Berberis vulgare
is moderately high (LD50 = 2.6 ± 0.22 g/kg b.w. inmice) [101].
By using sorbitol and breath hydrogen tests it has been
shown that BBR delays small intestinal transit time [102]; this
may account for part of its gastrointestinal and antidiarrheal
side effect [103]. The main mechanism of pharmacological
interaction of BBR involves cytochrome CYP3A4 and intesti-
nal P-glycoprotein, the major determinants of bioavailability
of orally administered drugs; in renal transplant recipients
the coadministration of BBR and cyclosporine A increases
the mean cyclosporine A half-life by 2.7 hours [104] thus
causing increased cyclosporine A bioavailability and reduced
metabolism. BBR is involved in different pharmacological
interactions: the drug displaces bilirubin from the albumin
about tenfold more than phenylbutazone and also warfarin,
thiopental, and tolbutamide from their protein binding sites,
increasing their plasma levels [105]. For the cited effects
the use of BBR should be avoided in jaundiced infants and
pregnant woman, even in small dosage [106].
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Figure 1: Molecular pathways modulated by BBR. (a) BBR could inhibit oxidative stress through AMPK activation that leads to a
downregulation of NADPH oxidase expression and an upregulation of the antioxidant enzymes SOD, CAT, and GSHpx. (b) BBR
administration could decrease glycemia through the increase of insulin receptor expression and the AMPK-modulated Glut-4 translocation.
(c) BBR could decrease circulating LDL by inhibiting NF-𝜅Bmodulated LOX-1 expression in endothelial cells and inducing LDLR expression
in hepatic cells. (d) BBR could inhibit the expression of MAO, leading to an upregulation of the mood-stabilizers neurotransmitters
norepinephrine, serotonin, and dopamine.
Oxidative stress
Atherosclerosis
Dyslipidemia
Depression
Hyperglycemia
Diabetes mellitus type 2
Berberis extract
Figure 2: BBR actions and target organs. Berberis extract administration could counteract, at least partially, depression, oxidative
stress, atherosclerosis, hypercholesterolemia, hyperglycemia, and diabetes mellitus type 2 protecting women from menopause-associated
pathologies.
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Although CYP3A4 is the well-known target, BBR also
inhibits CYP1A1 in vitro, therefore potentially interacting
with drugs metabolized by this cytochrome isoform as well
[107]. The impact of this observation in clinical practice has
to be evaluated since some environmental contaminants such
as aryl-hydrocarbons are metabolized by CYP1A1 [108].
Lin and colleagues reported that 24 hours of BBR treat-
ment upregulated the multidrug-resistant transporter (pgp-
170) expression in oral, gastric, and colon cancer cell lines
causing increased cell viability as compared to the effect of the
chemotherapeutic agent Paclitaxel. These results suggest that
BBR modulates the expression and function of pgp-170 that
leads to a reduced response to Paclitaxel in cancer cells [107].
Again, no clinical report of a significant pharmacological
interaction is yet available.
Overall there are a large number of recent clinical trials
supporting the short-term safe use of this nutraceutical,
especially when used at a lipid-lowering dosage.
7. Summary
The reduced estrogen level characterizingmenopause is asso-
ciated with the insurgence of discomforts and pathologies
which strongly affects the quality of life of many women.
There is growing evidence that berberine can, at least par-
tially, minimize the negative consequences on the organism
caused by low estrogens levels, without the unwanted side
effects associated with commonly prescribed HRT.While the
search for a HRT completely free of risks continues, BBR
could represent a safe and efficient tool to sustain women
during the menopausal transition.
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